RESPECT
Research type
Research Study
Full title
Registry for Percutaneous Electrochemotherapy (RESPECT)
IRAS ID
321459
Contact name
Tze Min / TMW Wah
Contact email
Sponsor organisation
Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
U1111-1280-1290,, Universal Trial Number (UTN)
Duration of Study in the UK
4 years, 4 months, 30 days
Research summary
Electrochemotherapy (ECT) is a technique used to treat cancer locally. It combines the use of an anti-cancer drug with electrodes that send electric signals directly in the tumour. The electric signals enable the drug to enter tumour cells, strongly increasing its toxic effect. A great advantage of this technique is that it does not affect healthy tissues surrounding the tumour. The procedure can be done percutaneously (pECT), meaning that electrodes can be placed at the tumour site through the skin instead of during open-surgery, with a much faster recovery time for the patients. ECT and pECT are already used in hospitals to treat many different types of cancer. The treatment of liver cancer with pECT is very promising as small studies have already shown that it is safe, efficient and well-tolerated by the patients. Data from large-scale multi-centre studies is however still missing. Therefore, RESPECT aims at collecting information from different healthcare centres in Europe on the use of pECT for liver cancer. The objectives are to report on efficiency, safety and impact on quality of life in a large and diverse population of patients. Patients with any type of liver cancer who are scheduled to receive pECT with the CLINIPORATOR® can be offered the possibility to participate in the study. As RESPECT is observational, it has no effect on the treatment and care patients will receive. In consenting to take part in the study, participants agree that relevant information about their cancer and treatment will be sent to a secure database. Information will be collected for a maximum period of 3 years.
Overall, RESPECT intends to provide healthcare professionals and health authorities with information on pECT for the treatment of liver cancer in order to improve patient care.REC name
London - Chelsea Research Ethics Committee
REC reference
23/PR/0423
Date of REC Opinion
26 Apr 2023
REC opinion
Favourable Opinion